The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
Abstract
APO‐I is a 48‐kDa cell‐membrane protein identical to the Fas antigen now designated CD95. It is a member of the NGF/TNF receptor superfamily. Anti‐APO‐I monoclonal antibody induces apoptosis in a variety of cell types expressing this antigen. We immunohistochemically investigated APO‐I expression in normal colon mucosa, 20 adenomas, 258 colon carcinomas and 10 liver metastases and carried out in vitro studies using a panel of colon‐carcinoma cell lines. Immunohistochemically, APO‐I was regularly expressed at the basolateral membrane of normal colon epithelia. In a minor fraction of colon adenomas and in 39.1% of colon carcinomas APO‐I expression was diminished and in 48.1% of carcinomas, predominantly of the non‐mucinous type, APO‐I expression was completely abrogated. The normal level of APO‐I in carcinomas was correlated with the mucinous type. Reduced/lost APO‐I expression was more frequent in rectal carcinomas. Complete loss of APO‐I was more frequent in tumors that had already metastasized. APO‐I expression in liver metastases essentially corresponded to that of the primary tumors. Comparative analysis with data from previous studies revealed that the mode of APO‐I expression is correlated with that of HLA‐A,B,C./β 2 m, HLA‐DR, HLA‐D‐associated invariant chain and of the secretory component. Surface expression of APO‐I was heterogeneous in colon‐carcinoma cell lines; SW480 expressed considerable amounts of APO‐I on all cells, while HT‐29 constitutively did less so and only in a minority of cells. Surface density of APO‐I and the fraction of positive cells in HT‐29 was enhanced by interferon‐gamma (IFN‐γ) and, additively, by tumor necrosis factor‐alpha (TNF‐α), whereas in SW480 APO‐I expression was not modulated by these cytokines. We conclude that neoplastic transformation of colon epithelium often leads to a loss of the physiologic, high level of surface APO‐I by giving rise either to a stable lack of APO‐I or to an IFN‐γ/TNF‐α‐sensitive phenotype of inducible APO‐I expression. © 1994 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,737
The Pathophysiology Of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.411 · Cited by 1,920
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Self-citationYonehara, S., Ishii, A., & Yonehara, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.5.1747 · Cited by 1,400
Molecular cloning and expression of a receptor for human tumor necrosis factor
Schall, T. J., Lewis, M., Koller, K. J., Lee, A., Rice, G. C., Wong, G. H. W., Gatanaga, T., Granger, G. A., Lentz, R., Raab, H., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90816-w · Cited by 964
Expression and structure of the human NGF receptor
Johnson, D., Lanahan, A., Buck, C. R., Sehgal, A., Morgan, C., Mercer, E., Bothwell, M., & Chao, M. (1986) · Cell · doi:10.1016/0092-8674(86)90619-7 · Cited by 963
Classification of human colorectal adenocarcinoma cell lines.
Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C., & Mabry, N. D. (1976) · PubMed · Cited by 949
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor
Loetscher, H., Pan, Y.-C. E., Lahm, H.-W., Gentz, R., Brockhaus, M., Tabuchi, H., & Lesslauer, W. (1990) · Cell · doi:10.1016/0092-8674(90)90815-v · Cited by 905
Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., & Trauth, B. C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50076-x · Cited by 834
Cited by
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Self-citationMolecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,439
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 628
Self-citationImmune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Self-citationCD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
Krammer, P. H. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60402-2 · Cited by 394
Self-citationSaitoh, Y., Waxman, I., West, A. B., Popnikolov, N. K., Gatalica, Z., Watari, J., Obara, T., Kohgo, Y., & Pasricha, P. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.24886 · Cited by 369
APOPTOSIS OF CRYPT EPITHELIAL CELLS IN ULCERATIVE COLITIS
IWAMOTO, M., KOJI, T., MAKIYAMA, K., KOBAYASHI, N., & NAKANE, P. K. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199610)180:2<152::aid-path649>3.0.co;2-y · Cited by 312
Regulation of the metastatic cell phenotype by sialylated glycans
Schultz, M. J., Swindall, A. F., & Bellis, S. L. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9359-7 · Cited by 303
Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity
Micheau, O., Solary, E., Hammann, A., Martin, F., & Dimanche-Boitrel, M.-T. (1997) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.783 · Cited by 281
Apoptosis and non-apoptotic deaths in cancer development and treatment response
de Bruin, E. C., & Medema, J. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.001 · Cited by 279
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.
Dowling, P., Shang, G., Raval, S., Menonna, J., Cook, S., & Husar, W. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1513 · Cited by 273
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Zhou, Z., Lafleur, E. A., Koshkina, N. V., Worth, L. L., Lester, M. S., & Kleinerman, E. S. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0092 · Cited by 31
Metadata
- Authors
- Möller, P., Koretz, K., Leithäuser, F., Brüderlein, S., Henne, C., Quentmeier, A., & Krammer, P. H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-05
- Volume
- 57
- Issue
- 3
- Pages
- 371-377
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2111181668
- Cited by
- 306
- References
- 31
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.